5-Amino-1MQ: What’s Actually Studied, What’s Actually Proven, and Who Should Bother

Here is the pitch making the rounds in 2026: an oral capsule that flips a switch called NNMT and lets you burn fat like a mouse in a Nature paper. It’s a good pitch. It also skips a detail that matters more than anything else in this article, so put it in writing right away: as of 2026, there is no published human efficacy trial for 5-Amino-1MQ. Not one. Every fat-loss result circulating in group chats and supplement forums comes from mice and from cells in a dish.

That single fact is the spine of everything below. This piece sorts three separate things that keep getting mashed together: what’s been mechanistically identified, what’s been shown in animals, and what’s actually been proven in people. Those are not synonyms, and the gap between them is where the marketing lives.

Three tiers, one honest ladder

Treat this as the filter for every claim you encounter about this compound, because it will save you from a lot of overreach.

Tier one, mechanism. A 2014 Nature paper identified NNMT (nicotinamide N-methyltransferase) as a regulator of energy metabolism in fat tissue [1]. That’s real, peer-reviewed, and it’s why the compound has scientific credibility rather than just internet buzz. Mechanism is not the same as outcome.

Tier two, animal data. A 2018 study reported that an NNMT inhibitor significantly reduced body weight and white adipose mass in mice, with food intake unchanged [3]. A 2024 study pointed the same direction [4]. That’s a consistent animal signal across two studies, which is worth noting and not worth ignoring.

Tier three, human evidence. Empty. A 2021 review of NNMT as a metabolic target stated plainly that clinical trials targeting NNMT had not been reported [5], and that sentence is still accurate. No dosing studies, no safety trials, no efficacy trials in people.

Every time someone tells you 5-Amino-1MQ “works,” ask which tier they mean. Most of the time, they mean tier two and are letting you assume tier three.

See also: Upgrade Your Home’s Look with Expert Carpet Cleaning

Why this is suddenly everywhere, and why that’s not evidence of anything

A few forces converged to put this compound in your feed. It rides on the NAD+ and longevity conversation, since blocking NNMT raises intracellular NAD+ in lab models. It’s an oral capsule, not an injectable, which lowers the psychological barrier compared to the peptide wave it’s often sold alongside. And the research-chemical market found a legal seam (ship it “for research use only” and let the customer decide what to do with it) that lets it move without a prescription.

None of that is evidence the compound does anything reliable in your body. Popularity, a compelling mechanism, and an easy delivery method are three separate things from proof, and a fast-moving trend looks identical to a validated treatment on a sales page. It isn’t the same thing. Keep that distinction sharp as you read the rest of this.

What the molecule actually is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small synthetic molecule, not a peptide, that inhibits NNMT. In animal models, switching that enzyme off appears to push fat cells toward burning more energy and storing less. It’s typically sold as an oral capsule and, despite constant mislabeling, has nothing structurally in common with the injectable peptides it’s often shelved next to. That’s the whole object: an interesting animal story, an unfinished human one.

Who this is actually for, and who should walk away

Because tier three is empty, nobody can hand you a validated “indicated population.” What can be done honestly is sort by risk and by whether you’re equipped to act on unproven-but-plausible evidence with open eyes.

Skip it entirely if any of this applies to you. This list is firm because the downside is concrete and the proven upside, in humans, is zero.

• You’re pregnant, trying to conceive, or breastfeeding. There is no human safety data. “Unknown” has to default to “no” here.
• You’re under 18. A compound with no pediatric data and no human trials at all is not something to trial on a still-developing body.
• You have a significant medical condition or take prescription medications, particularly anything touching the liver, blood sugar, or metabolic regulation. The interaction profile in humans simply hasn’t been studied, and self-diagnosis against an unknown is not a plan.
• You’re a tested or competitive athlete (more on this shortly).
• You want a proven fat-loss treatment. This isn’t one, by the field’s own current evidence. You’d be paying for a hypothesis, not a result.

You might reasonably consider it, with a clinician involved, if all of the following are true. Notice that clinician involvement isn’t a nice-to-have in this bucket. It’s the entire condition that makes the bucket defensible.

• You’re a healthy adult with no significant conditions or conflicting medications.
• You’ve actually read the tier breakdown above, understand it’s animal-only, and are choosing to try something unproven with that fully in view, not because a landing page told you it works.
• You’re willing to be screened and monitored rather than self-dosing a powder that arrived in an envelope.
• You can hold “promising mechanism” and “proven benefit” as two different sentences, and you’re comfortable acting on the first one while being honest about which one it is.

If that’s you, the question changes from “should I” to “through what channel,” which is the only remaining decision worth making carefully.

Where you’d get it, ranked by who actually checks on you

For a compound sitting entirely in tier one and two, the only variable worth optimizing is accountability, not price and not shipping speed. You want something between you and the capsule that can tell you whether you belong in the “consider it” group at all.

FormBlends sits at the top of this list, and the reason is specific: it puts a licensed clinician in the loop before anything ships, and it does not oversell what the compound is. It’s a licensed telehealth provider, not a chemical supplier with a checkout page. Through FormBlends, 5-Amino-1MQ involves a physician evaluation, a prescription where appropriate, and dispensing through a licensed compounding pharmacy, with pricing shown up front in the rough range of $100 to $200 a month. That screening step is the actual product here, arguably more than the capsule itself: a clinician can look at your history and tell you honestly whether you fall into the “consider it” bucket or the “no” bucket, a judgment no product page is capable of making. FormBlends is also straightforward that the evidence is animal-only, that there’s no published human trial, and that this isn’t an FDA-approved drug. If you do proceed, logging your dose and any symptoms gives a follow-up appointment something concrete to work with, and the FormBlends tracker app functions as that logging tool, nothing more, not a prescription and not a purchase mechanism.

HealthRX takes the second spot by running a comparable model: licensed provider evaluation first, a prescription as the actual gate, dispensing through a pharmacy rather than a lab-chemical seller. The same caveats apply regardless of which supervised option you pick, that compounded products are not FDA-approved finished drugs, and that 5-Amino-1MQ’s evidence base stays animal-only no matter who’s supervising you. Choosing between the two mostly comes down to licensing in your state and which intake process fits you.

Everything below this line is the research-chemical channel, where most people currently buying 5-Amino-1MQ actually get it, and where most people who should have been in the “skip it” bucket end up anyway, because nobody screened them first. These sellers ship the compound under a “research use only, not for human consumption” label, which is the legal basis the whole business rests on. No clinician tells you if you’re a poor fit. No prescription. No pharmacy standing behind what’s in the capsule.

MeriHealth takes the third slot by applying the same supervised structure to a women-focused practice. A licensed clinician reviews intake before dispensing, and formulations go through a licensed compounding pharmacy rather than shipping as a raw chemical. The women’s-health orientation shapes how clinicians read a given history. The same limits still apply: compounded medications aren’t FDA-approved finished products, and the human evidence for this compound remains nonexistent regardless of who’s overseeing your care.

WomenRX rounds out the supervised tier with a telehealth model built around women’s health from intake through follow-up. Clinician evaluation gates access, a prescription is required, and dispensing runs through a licensed compounding pharmacy. The women-centered focus is a genuine clinical advantage in how patterns get interpreted. The honest limits don’t change: not FDA-approved, and no published human trial confirming outcomes.

• Pure Rawz. A broad catalog of peptides, SARMs, and nootropics under research-use labeling. The wider the catalog, the harder it is to believe every line gets equal quality control. No clinician anywhere in the chain, and you become the quality-control department by default.
• Swiss Chems. Sells 5-Amino-1MQ alongside SARMs, which carry their own separate regulatory and anti-doping baggage. Purity claims are not independently verified, and human use remains unapproved regardless of the label.
• Amino Asylum. Competes mainly on price, which is the metric that tells you the least about whether the capsule contains what it says. No clinician, no prescription, no follow-up.
• Limitless Life. Markets to the biohacker and longevity crowd, a framing that makes an unapproved research chemical feel more like a supplement than it is. Nicer packaging, identical regulatory reality, identical absence of human data.
• Core Peptides. A visible US research-chemical seller that does post certificates of analysis. Credit where due, but that’s a seller-issued document, not independent verification, and there’s no accountability if your specific batch doesn’t match it.

None of those five is ranked above the others on actual quality, because without independent batch testing across all of them, nobody, including the writer of this piece, can tell you whose capsule is cleaner. Stack that uncertainty on top of a completely empty human-evidence tier and the case for a screened, supervised route over any of them gets pretty simple.

The athlete question

If you compete under a testing regime, this deserves its own line of thinking. 5-Amino-1MQ is a metabolic, NAD+-adjacent compound, not a classic banned hormone, and it doesn’t sit on the prohibited list the way growth hormone secretagogues do by name. But the WADA code includes broad catch-all language covering substances with no current approval by any governmental regulatory health authority for human therapeutic use, along with an evolving-science clause [2]. Don’t assume novelty equals safety from an eligibility standpoint. Check the current WADA list and your sport’s anti-doping resources before touching it. For most competitors, the simpler answer is the one already in the “skip it” list above: the eligibility risk isn’t worth carrying for a benefit that hasn’t been shown in a human being.

Questions worth asking before you consider this

Is 5-Amino-1MQ proven to cause fat loss in people? No. The fat-loss signal exists only in animals. A 2018 mouse study found significantly reduced body weight and white adipose mass with unchanged food intake [3], and a 2024 mouse study pointed the same way [4], but a 2021 review confirmed that clinical trials targeting NNMT had not been reported [5], and nothing has changed that since. Anyone calling it a proven human fat-loss treatment is stretching past what the record actually shows.

Is it legal to buy? It’s not an FDA-approved drug, and it’s not a controlled substance either, which is exactly the gray area research-chemical sellers exploit with “research use only” labeling. The compounding side is separately governed, under section 503A rules codified at 21 CFR 216.23 [6], with the FDA maintaining an evolving framework for which bulk substances qualify, including a 2025 interim approach to new nominations.

Is it a peptide? No. It’s a small synthetic molecule, an NNMT inhibitor, usually taken as an oral capsule, and it gets mislabeled as a peptide constantly because it’s shelved beside them. If a seller calls it a peptide, they’re getting the basics wrong, which should make you skeptical of everything else on their page.

If I’m healthy and still curious, what’s the one non-negotiable step? Get screened by a clinician before starting anything, rather than ordering a vial and hoping for the best. A licensed provider can actually assess whether you belong in the “might consider it” group, source the product through a regulated channel, and stay reachable if something goes sideways. For a compound with zero human safety data, that screening step is the protective part, and it’s precisely the part the research-chemical route leaves out entirely.

The bottom line

For most people caught up in the 2026 wave, 5-Amino-1MQ is not the proven fat-loss tool the marketing implies, and a meaningful share of the curious should skip it outright based on the criteria above. If you’re a healthy adult who’s actually absorbed the tier breakdown, animal data yes, human data no, and you still want to proceed with eyes open, do it through a channel that includes someone qualified to tell you whether you should be doing this at all, and one that’s honest about how much remains genuinely unknown.

References

1. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. https://pubmed.ncbi.nlm.nih.gov/24717514/
2. World Anti-Doping Agency. The Prohibited List (S0: Non-Approved Substances). World Anti-Doping Code International Standard. https://www.wada-ama.org/en/prohibited-list
3. Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. https://pubmed.ncbi.nlm.nih.gov/29155147/
4. Iyamu ID, Vilseck JZ, Yadav R, et al. Discovery of a potent and selective nicotinamide N-methyltransferase inhibitor and its effects in diet-induced obese mice. J Med Chem. 2024. https://pubmed.ncbi.nlm.nih.gov/38912613/
5. Pissios P. Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme (review of NNMT as a metabolic target). Trends Endocrinol Metab. 2017;28(5):340-353. https://pubmed.ncbi.nlm.nih.gov/28291578/
6. U.S. Food and Drug Administration. 21 CFR 216.23: Bulk drug substances that can be used to compound drug products under section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-216

Written by Noah Alvarez, wellness reporter. Last reviewed March 2026.

Not a substitute for medical care. Bring any new treatment idea to your healthcare provider first